Pegaspargase (Oncaspar®) powder for solution for injection/infusion. HTA ID: 20003

Assessment Status Rapid Review Complete
HTA ID 20003
Drug Pegaspargase
Brand Oncaspar®
Indication As a component of antineoplastic combination therapy in acute lymphoblastic leukaemia in paediatric patients from birth to 18 years.
Assessment Process
Rapid review commissioned 05/02/2020
Rapid review completed 13/03/2020
Rapid review outcome A full HTA is not recommended. The NCPE recommends that pegaspargase (Oncaspar®) be considered for reimbursement*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.

The HSE has approved reimbursement, March 2020